[Therapy of hormone refractory prostatic carcinoma].
In patients with hormone-resistant prostate cancer primary androgen deprivation eventually fails. The begin of secondary treatment is depending on clinical symptoms; since survival cannot be prolonged in progressive disease improvement of quality of life is of paramount importance. Altering of endocrine treatment and antiandrogen withdrawal can cause a transient improvement of the sense of well being. Single agent chemotherapy with little side effects should be preferred as compared with polychemotherapy since response rates do not exceed 30%. Although 2/3 of the patients benefit from chemotherapy there is however no proof that it is superior to symptom-related pain relief. The indication for surgical management such as TURP and spinal cord decompression is depending on clinical symptoms from local progression and systemic disease.
Bex
A
A
Urologische Klinik und Poliklinik, Universitätsklinikum Essen.
Rübben
H
H
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011788:Quality of Life; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal